According to the latest filings from the US Securities and Exchange Commission (SEC), biotechnology company Inovio Pharmaceuticals has officially suspended and terminated its at-the-market (ATM) equity offering prospectus previously established with investment bank Oppenheimer & Co.

This decision means that Inovio Pharmaceuticals will temporarily be unable to flexibly issue new shares and raise funds in the open market through the ATM financing mechanism. The ATM issuance model typically allows listed companies to issue shares opportunistically based on market conditions as needed, serving as a flexible and efficient financing tool. The termination of this plan may reflect an adjustment in the company’s current financing strategy or considerations regarding the market environment. Market participants will closely monitor the potential impact of this move on the company’s future funding status and the progress of its research and development pipeline.